Billing and Coding Tools

To provide administrative assistance in your practice, Solstice offers the following Billing and Coding Tools:

J-code for MYOBLOC: J0587

ICD-9-CM^a code for spasmodic torticollis (CD): 333.83

CPT^b code for chemodenervation of muscle(s), cervical spinal muscle(s) (eg, for spasmodic torticollis): 64613^c

EMG codes for chemodenervation:
95873 Electrical stimulation for guidance in conjunction
with chemodenervation
95874 Needle electromyography for guidance in conjunction
with chemodenervation

Vial Size	NDC Numbers^d
2,500 Units/0.5 mL 5,000 Units/1.0 mL 10,000 Units/2.0 mL	10454-710-10 10454-711-10 10454-712-10

^aICD-9-CM codes are based on the World Health Organization (WHO) International Classification of Diseases, 9th edition. Solstice assumes no liability for information contained herein. Solstice claims no ownership or other interest in the ICD-9-CM codes. ICD-9-CM codes are provided herein for reference only. Only a patient’s health care provider may determine the appropriate ICD-9-CM code.

^bCPT^® codes are copyrighted property of the American Medical Association (AMA). Solstice assumes no liability for any of the information contained herein. Solstice claims no ownership or other interest in the CPT codes. CPT codes are provided herein for reference only and are not intended to convey any endorsement or sponsorship by, or affiliation with, the AMA.

^cCPT code 64613 is the usual CPT code for administration of MYOBLOC for the treatment of spasmodic torticollis (otherwise known as cervical dystonia). Other administration codes may be appropriate as determined by the patient’s health care provider.

^dPlease note that for billing purposes, some payers may require an 11-digit code based on the NDC number. Therefore, a zero must be entered into the 6th position (example: "10454-0710-10"). This is consistent with the Red Book and First DataBank listings.

See Important Safety Information below.

Important Safety Information

Distant Spread of Toxin Effect

Postmarketing reports indicate that the effects of MYOBLOC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These may include asthenia, generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in treated for spasticity and other conditions, particularly in those patients who have underlying conditions that would predispose them to these symptoms. In unapproved uses, including spasticity in children and adults, and in approved indications, cases of spread of effect have occurred at doses comparable to those used to treat cervical dystonia and at lower doses. (See WARNINGS, PRECAUTIONS, and OVERDOSE sections of full Prescribing Information).

Myobloc^® (rimabotulinumtoxinB) Injection is indicated for the treatment of adults with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia. Units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products.

Before administering MYOBLOC, physicians should consult the full Prescribing Information and Medication Guide.

The most frequently reported adverse events with MYOBLOC are dry mouth, dysphagia, dyspepsia, and injection site pain. The vast majority of these adverse events were mild to moderate, temporary, self-resolving, and more common with higher doses. These adverse events may occur within the first week following treatment and may have a duration of several months. In controlled clinical trials, few patients (<1%) stopped treatment due to dry mouth or dysphagia. There is a reduced frequency of dry mouth and dysphagia reported with continued treatment. Dysphagia has commonly been reported by patients treated with all botulinum toxins for cervical dystonia. Units of biological activity of MYOBLOC cannot be compared to or converted into units of any other botulinum toxin products.

Caution should be exercised when administering MYOBLOC to individuals with motor neuron disease (e.g., amyotrophic lateral sclerosis), peripheral motor neuropathic diseases (e.g., motor neuropathy) or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome). These patients may be at increased risk of clinically significant systemic effects including severe dysphagia and respiratory compromise from typical doses of MYOBLOC. In these patients, rare cases of dysphagia severe enough to cause aspiration pneumonia or to warrant the insertion of a gastric feeding tube have also been reported.

Coadministration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.

Click here for Important Safety Information, full Prescribing Information and Medication Guide.

Important Safety Information | Prescribing Information Terms of Use | Privacy Policy